Late lead optimisation of orally available potassium channel inhibitors for the treatment of psoriasis

- Metrion Bioscience Ltd （Metrion）是一家离子通道专业合同研究机构，最近开始建立其药物发现和开发能力。该公司总部位于剑桥格兰塔公园，其核心专长是离子通道药物发现和神经科学。Metrion的研发重点是设计和发现用于治疗衰弱性自身免疫性疾病的分子。管理团队和顾问在该领域拥有丰富的经验，之前曾筹集过大量股权融资，并在向临床提供分子方面拥有良好的记录。- Metrion率先发现有可能改变牛皮癣潜在病因的口服药物。牛皮癣的成功治疗主要只提供症状缓解，但这创造了一个70亿美元的市场。Metrion的方法有可能从根本上改变/停止影响患者和医疗保健系统的牛皮癣的进展。Metrion将利用其药物发现专业知识识别与自身免疫性疾病和神经退行性疾病相关的钾通道小分子抑制剂。在这个项目之后，对这些铅分子的进一步修饰将允许产生用于治疗其他自身免疫性疾病的口服活性药物。”

"-- Metrion Bioscience Ltd (Metrion) is an ion channel specialist contract research organisation and has recently begun building its drug discovery and development capability. The company is based at Granta Park, Cambridge, with a core expertise in ion channel drug discovery and neuroscience. Metrion's R&D is focused on designing and discovering molecules for the treatment of debilitating Autoimmune disorders. The management team and advisors have extensive experience in this field and have previously raised significant equity funding and have a track record in delivering molecules to the clinic.-- Metrion is pioneering the discovery of oral medicines with the potential to change the underlying causes of psoriasis. The successful treatments for psoriasis predominantly provide symptomatic relief only, nevertheless this has created a $7bn market. Metrion's approach has the potential to radically modify/halt the progression of psoriasis impacting the patient and the healthcare system.-- Metrion through this grant will exploit its drug discovery expertise to identify small molecule inhibitors of potassium channels which has been linked to autoimmune disease and neurodegeneration. Further modification of these lead molecules subsequent to this project will allow the generation of orally active agents for the treatment of other autoimmune disease."